Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:10 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 520 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Drug Resistance Clear all

Conditions: Pneumonia, Pulmonary Tuberculosis
Interventions: Interferon Gamma; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1994 – 2003
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Drug-Resistant Focal Epilepsy
Interventions: Implantable minimaly invasive brain stimulator; Device
Lead sponsor: Precisis US, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: New York, New York

Conditions: Tuberculosis, Non-Tuberculosis Mycobacteria
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 215 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Breast Cancer, Cancer, Lung Cancer, Ovarian Cancer
Interventions: Vinorelbine, XR9576; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2001
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Tuberculosis, Drug-resistant Tuberculosis, Adherence, Medication, Adherence, Patient
Interventions: Electronic DOT, In-person DOT; Other
Lead sponsor: Centers for Disease Control and Prevention; Federal
Eligibility: 12 Years and older
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 4
States / cities: Brooklyn, New York • Jackson Heights, New York • New York, New York + 1 more

Conditions: Late Life Depression, Cognitive Decline, Depressive Disorder, Treatment-Resistant, Levodopa, Gait Impairment
Interventions: L-Dopa, Placebo; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 60 Years and older
Enrollment: 79 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania • Nashville, Tennessee

Conditions: Serious Bacterial Infection
Interventions: ATM-AVI, BAT; Combination Product · Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Parkinson Disease
Interventions: Resistance Exercise via Negative Eccentric Work, Standard care exercise training; Behavioral
Lead sponsor: University of Utah; Other
Eligibility: 40 Years to 90 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Wilms' Tumor, Sarcoma, Adenaocortical Carcinoma, Refractory Cancer, Coldrhood Cancer
Interventions: Tariquidar; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 2 Years to 18 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2016
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Epilepsy Intractable
Interventions: Not listed
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Healthcare Associated Infections, Methicillin Resistant Staphylococcus Aureus, Multi Drug Resistant Organisms
Interventions: Arm 2: Decolonization; Drug
Lead sponsor: University of California, Irvine; Other
Eligibility: 12 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 52
States / cities: West Hills, California • Thornton, Colorado • Bradenton, Florida + 42 more

Conditions: HIV, Insulin Resistance, Food Insecurity
Interventions: NOURISH Food Box; Other
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years and older
Enrollment: 675 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Tulsa, Oklahoma

Conditions: Mitochondrial Diseases, Drug Resistant Epilepsy, Leigh Disease, Leigh Syndrome, Mitochondrial Encephalopathy (MELAS), Pontocerebellar Hypoplasia Type 6 (PCH6), Alpers Disease, Alpers Syndrome
Interventions: Vatiquinone, Placebo; Drug · Other
Lead sponsor: PTC Therapeutics; Industry
Eligibility: Up to 20 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 12
States / cities: San Diego, California • Stanford, California • New Haven, Connecticut + 7 more

Conditions: Epilepsy, Alzheimer Disease, Epilepsy Intractable
Interventions: NPT 2042 (bumetanide analog) or Matching Placebo; Drug
Lead sponsor: NeuroPro Therapeutics, Inc.; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Epilepsy
Interventions: observation of VNS stimulation effects; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Prostate Cancer
Interventions: Abiraterone acetate, Prednisone, Radium-223 dichloride, cabazitaxel, Carboplatin, Enzalutamide; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older · Male only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 2
States / cities: New York, New York

Conditions: Depression, Depressive Disorder, Metabolic Syndrome
Interventions: Exercise; Behavioral
Lead sponsor: California State University, San Marcos; Other
Eligibility: 18 Years to 40 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: San Marcos, California

Conditions: Aging, Mortality, All-cause Mortality, Life Expectancy, Cardiovascular Diseases, Neoplasms, Cognitive Dysfunction, Metabolic Syndrome, Frailty, Musculoskeletal Disease, Neurodegenerative Disease, Dementia, Activities of Daily Living, Health Related Quality of Life, Environmental Exposure, Occupational Diseases, Health Equity, Social Determinants of Health, Physical Disability
Interventions: Multi-Domain Ecological and Clinical Data Linkage; Other
Lead sponsor: Longevity Metrics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,000,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2099
U.S. locations: 1
States / cities: Boulder, Colorado

Conditions: Neoplasms, Precancerous Conditions
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2012
U.S. locations: 2
States / cities: Bethesda, Maryland

Conditions: Ovarian Cancer
Interventions: Decitabine, Carboplatin, Paclitaxel, Selinexor; Drug
Lead sponsor: Loyola University; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 1
States / cities: Maywood, Illinois

Conditions: Venous Leg Ulcer
Interventions: allo-APZ2-CVU, Placebo; Drug
Lead sponsor: RHEACELL GmbH & Co. KG; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 4
States / cities: Hialeah, Florida • Miami, Florida • Boston, Massachusetts + 1 more

Conditions: Gestational Diabetes, Pregnancy Related
Interventions: Insulin; Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 430 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Rochester, New York • Philadelphia, Pennsylvania

Conditions: HIV Infections, Pregnancy
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years to 60 Years · Female only
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 28
States / cities: Birmingham, Alabama • La Jolla, California • Long Beach, California + 17 more

Conditions: Pulmonary Multi-drug Resistant Tuberculosis
Interventions: No Intervention; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: Not listed
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Raleigh, North Carolina

Search by objective public record fields.

Interferon Gamma for Drug Resistant Tuberculosis

EASEE® System Pivotal Study for the United States of America

Sputum Pharmacokinetics of TB Drugs and Bacterial Drug Resistance

Vinorelbine and XR9576 to Treat Cancer

An Evaluation of Traditional Directly Observed Therapy (DOT) and Electronic DOT for TB Treatment

Dopaminergic Dysfunction in Late-Life Depression

Efficacy, Safety, and Tolerability of ATM-AVI in the Treatment of Serious Infection Due to MBL-producing Gram-negative Bacteria

Strength Training and Medication Effects in Parkinson Disease Effects on Hypokinesia in Parkinson Disease

Phase I Trial of Tariquidar (XR9576) in Combination With Doxorubicin, Vinorelbine, or Docetaxel in Pediatric Patients With Solid Tumors

Microgrid II - Electrocorticography Signals for Human Hand Prosthetics

Active Bathing to Eliminate Infection (ABATE Infection) Trial

Nutrition to Optimize, Understand, and Restore Insulin Sensitivity in HIV for Oklahoma

A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy

Safety and Pharmacokinetic Study of NPT 2042 Soft-gelatin Capsules Administered Orally to Healthy Adult Subjects

Assessment of Effect of Vagal Nerve Stimulator (VNS) on Electrocorticograms Recorded by Responsive Neurostimulator (RNS) in Patients With Drug Resistant Epilepsy

Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)

Does Antidepressant Use Blunt Adaptations to Exercise?

Human Observatory Study

Collection of Blood, Bone Marrow, Tumor or Tissue Samples

Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer

Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Therapy-resistant CVU (Phase III)

Strict Versus Permissive Thresholds for Initiation of Pharmacotherapy in Gestational Diabetes (START 2)

Study of Perinatal Transmission of Zidovudine-Resistant HIV Among Pregnant Women Treated With Zidovudine

A Prospective Patient Registry of Patients Exposed to Bedaquiline